Table 3.
Clinicopathologic characteristics of patients with stage IB3 cervical cancer in the NACT-sensitive and ARH groups.
| Variables | Unadjusted | Adjusted | ||||
|---|---|---|---|---|---|---|
| NACT-sensitive group (n = 314) | ARH group (n = 827) | p | NACT-sensitive group (n = 311) | ARH group (n = 525) | p | |
| Age (years) | 45.13 ± 7.672 | 47.20 ± 8.672 | <0.001 | 45.07 ± 7.300 | 45.97 ± 7.154 | 0.080 |
| Initial tumor diameter(cm) | 5.401 ± 0.817 | 5.387 ± 1.036 | 0.815 | 5.400 ± 0.820 | 5.414 ± 1.084 | 0.834 |
| Histological type | 0.377 | 0.912 | ||||
| SCC | 284 (90.5%) | 726 (87.8%) | 281 (90.4%) | 470 (89.5%) | ||
| AC | 24 (7.6%) | 75 (9.1%) | 24 (7.7%) | 43 (8.2%) | ||
| SAC | 6 (1.9%) | 26 (3.1%) | 6 (1.9%) | 12 (2.3%) | ||
| Parametrial involvement | 0.595 | 0.916 | ||||
| Negative | 310 (98.7%) | 821 (99.3%) | 307 (98.7%) | 520 (99.0%) | ||
| Positive | 4 (1.3%) | 6 (0.7%) | 4 (1.3%) | 5 (1.0%) | ||
| Vaginal margin invasion | 1.000 | 1.000 | ||||
| Negative | 311 (99.0%) | 818 (98.9%) | 308 (99.0%) | 519 (98.9%) | ||
| Positive | 3 (1.0%) | 9 (1.1%) | 3 (1.0%) | 6 (1.1%) | ||
| LVSI | 0.001 | <0.001 | ||||
| Negative | 297 (94.6%) | 724 (87.5%) | 294 (94.5%) | 456 (86.9%) | ||
| Positive | 17 (5.4%) | 103 (12.5%) | 17 (5.5%) | 69 (13.1%) | ||
| Stromal invasion | <0.001 | <0.001 | ||||
| ≤1/2 | 164 (52.2%) | 237 (28.6%) | 163 (52.5%) | 148 (28.2%) | ||
| >1/2 | 119 (37.9%) | 549 (66.4%) | 118 (37.9%) | 355 (67.6%) | ||
| Unknown | 31 (9.9%) | 41 (5.0%) | 30 (9.6%) | 22 (4.2%) | ||
| Postoperative radiotherapy | <0.001 | <0.001 | ||||
| No | 206 (65.6%) | 388 (46.9%) | 203 (65.3%) | 253 (48.2%) | ||
| Yes | 108 (34.4%) | 439 (53.1%) | 108 (34.7%) | 272 (51.8%) | ||
NACT, neoadjuvant chemotherapy; ARH, abdominal radical hysterectomy; SCC, squamous cell carcinoma; AC, adenocarcinoma; SAC, adenosquamous carcinoma; LVSI, lymphovascular space invasion.